Mudalsha Ravina1, Søren Hess, Mahesh Singh Chauhan, Mattakorottu Joseph Jacob, Abass Alavi. 1. From the *Department of Nuclear Medicine, Army Hospital Research and Referral, New Delhi, India; †Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark; and ‡Division of Nuclear Medicine, University of Pennsylvania Perelman School of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA.
Abstract
PURPOSE: Thrombosis in cancer may manifest itself as venous thromboembolic disease or tumor thrombosis (TT). We present our experience with incidentally detected TT on FDG PET/CT in 21 oncologic patients. PATIENTS AND METHODS: We retrospectively reviewed all FDG PET/CT examinations during a 5-year period at the Army Hospital Research and Referral in New Delhi, India, and included all oncology cases with FDG-avid thrombosis in the report. The diagnosis of TT was based on FDG-avid solid masses inside the vessels in patients with known malignancy. The SUVmax was calculated. RESULTS: Twenty-one patients were included; the most common malignancies were renal cell carcinoma (n=6), hepatocellular carcinoma (n=3), and lung cancer (n=3). Indication for the scan was initial staging (n=15) and suspected recurrence (n=6). Several vessels were affected, the most common was the inferior vena cava (n=14), but most other major branches of the venous vasculature was represented, and some patients had thrombi in several vessels. FDG uptake was linear in 7 patients, linear with a dilated vessel in 6 patients, and focal in 7 patients. The mean SUVmax of the primary tumors was 10.3 (range, 2.6-31.2; median, 6.9), and the mean SUVmax of the thrombi was 7.85 (range, 1.7-23.2; median, 6.1). All but 2 patients had additional FDG-avid foci besides the thrombus. CONCLUSIONS: This study supports results from other smaller studies regarding the usefulness of FDG PET/CT in TT and corroborates the hypothesis that the SUVmax and the patterns of FDG uptake can be helpful for differentiating BT from TT in oncological patients.
PURPOSE:Thrombosis in cancer may manifest itself as venous thromboembolic disease or tumor thrombosis (TT). We present our experience with incidentally detected TT on FDG PET/CT in 21 oncologic patients. PATIENTS AND METHODS: We retrospectively reviewed all FDG PET/CT examinations during a 5-year period at the Army Hospital Research and Referral in New Delhi, India, and included all oncology cases with FDG-avid thrombosis in the report. The diagnosis of TT was based on FDG-avid solid masses inside the vessels in patients with known malignancy. The SUVmax was calculated. RESULTS: Twenty-one patients were included; the most common malignancies were renal cell carcinoma (n=6), hepatocellular carcinoma (n=3), and lung cancer (n=3). Indication for the scan was initial staging (n=15) and suspected recurrence (n=6). Several vessels were affected, the most common was the inferior vena cava (n=14), but most other major branches of the venous vasculature was represented, and some patients had thrombi in several vessels. FDG uptake was linear in 7 patients, linear with a dilated vessel in 6 patients, and focal in 7 patients. The mean SUVmax of the primary tumors was 10.3 (range, 2.6-31.2; median, 6.9), and the mean SUVmax of the thrombi was 7.85 (range, 1.7-23.2; median, 6.1). All but 2 patients had additional FDG-avid foci besides the thrombus. CONCLUSIONS: This study supports results from other smaller studies regarding the usefulness of FDG PET/CT in TT and corroborates the hypothesis that the SUVmax and the patterns of FDG uptake can be helpful for differentiating BT from TT in oncological patients.